Zydus, MSN Launch First Generic of Adempas (Riociguat) in US Across 5 Strengths

Zydus, MSN Launch First Generic of Adempas (Riociguat) in US Across 5 Strengths

New Delhi: Zydus Lifesciences Limited, in partnership with MSN Laboratories Private Limited, has launched the first generic version of Adempas (riociguat) in the United States across five strengths,...

Zydus launches in U.S. MSN Labs generic of Bayer’s PAH drug

Zydus Lifesciences and MSN Labs launch US generic Riociguat (Bayer’s Adempas) for PAH and CTEPH, first-to-market.

Zydus Lifesciences launches first generic Riociguat in US

Zydus Lifesciences and MSN Laboratories launch the first generic Riociguat tablets in the US across five strengths after USFDA approval.

Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S - Press Network of India

Bengaluru: Zydus Lifesciences Limited (Zydus), in partnership with MSN Laboratories Private Limited (MSN), today announced the launch of Riociguat Tablets, 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg, in the United States. Zydus and MSN are the first companies to launch a generic version of Adempas® (riociguat) in the U.S. market. The […]

Zydus, MSN launch generic riociguat in US

Riociguat Tablets are approved by the USFDA as a generic equivalent of Adempas Tablets in five strengths

Zydus Lifesciences rises on launching Riociguat Tablets in US in partnership with MSN Laboratories

Mumbai, October 6 (Udaipur Kiran): Zydus Lifesciences is currently trading at Rs. 1152.05, up by 13.55 points or 1.19% from its previous closing of Rs. 1138.50 on the BSE. The scrip opened at Rs. 1146.55 and has touched a high and low of Rs. 1,156.15 and Rs. 1146.55 respectively. So far 232 shares were traded ... Zydus Lifesciences rises on launching Riociguat Tablets in US in partnership with MSN Laboratories